Terbinafine: an update.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of American Academy of Dermatology

• Publication date

  1997-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0190-9622(97)70076-8PMID 9418768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence and cause of aplastic anemia, hemolytic anemia, agranulocytosis and thrombocytopenia.

  2009cited by this paper
• Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers

  2004cited by this paper
• Taste loss to terbinafine: a case-control study of potential risk factors.

  2003cited by this paper
• Adverse reactions to drugs

  1998cited by this paper
• Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients.

  1998cited by this paper
• Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis.

  1997cited by this paper
• Safety of oral terbinafine : Results of a postmarketing surveillance study in 25 884 Patients

  1997cited by this paper
• Hypersensitivity reaction to terbinafine.

  1997cited by this paper
• Onychomycosis in children: prevalence and treatment strategies.

  1997cited by this paper
• The response to Lamisil of dermatophyte infection in diabetic patients

  1996cited by this paper
• Treatment of dermatophyte nail infections: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy.

  1996cited by this paper
• Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients.

  1996cited by this paper
• A randomized double‐blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis

  1996cited by this paper
• Therapeutic efficacy of terbinafine in the treatment of three children with tinea tonsurans.

  1996cited by this paper
• Efficacy of terbinafine treatment of tinea capitis in children varies according to the dermatophyte species

  1996cited by this paper
• ONYCHOMYCOSIS TREATED WITH A SHORT COURSE OF ORAL TERBINAFINE

  1996cited by this paper
• Intermittent Therapy with Terbinafine for Dermatophyte Toe‐Onychomycosis: A New Approach

  1996cited by this paper
• The development of green vision in association with terbinafine therapy.

  1996cited by this paper
• A 12–week treatment for dermatophyte toe onychomycosis terbinafine 250mg/day vs. itraconazole 200mg/day—a double‐blind comparative trial

  1996cited by this paper
• Treatment of Candida nail infection with terbinafine.

  1996cited by this paper
• Economic evaluation of antifungal agents in the treatment of toenail onychomycosis in Germany.

  1996cited by this paper
• The effects of repeated dermal application of capsaicin to the human skin on pain and vasodilatation induced by intradermal injection of acid and hypertonic solutions

  1996cited by this paper
• Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals

  1996cited by this paper
• Clinical and Economic Factors in the Treatment of Onychomycosis

  1996cited by this paper
• German randomized double–blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection

  1996cited by this paper
• Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study

  1996cited by this paper
• Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model.

  1996cited by this paper
• Toxic epidermal necrolysis induced by terbinafine in a patient on long‐term anti‐epileptics

  1996cited by this paper
• Long‐term evaluation of terbinafine 250 and 500 mg daily in a 16‐week oral treatment for toenail onychomycosis

  1996cited by this paper
• Acute generalized exanthematous pustulosis induced by terbinafine.

  1996cited by this paper
• Long‐term evaluation of terbinafine 250 and 500 mg daily in a 16‐week oral treatment for toenail onychomycosis

  1996cited by this paper
• Postmarketing surveillance of oral terbinafine in the UK: report of a large cohort study.

  1996cited by this paper
• Use of terbinafine in HIV‐positive subjects: pilot studies in onychomycosis and oral candidiasis

  1996cited by this paper
• Pharmacoeconomic Analysis of Oral Treatments for Onychomycosis:: A Canadian Study

  1995cited by this paper
• Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine.

  1995cited by this paper
• OPEN RANDOMIZED COMPARISON OE ITRACONAZOLE VERSUS TERBINAEINE IN ONYCHOMYCOSIS

  1995cited by this paper
• Serum sickness-like reaction associated with oral terbinafine therapy

  1995cited by this paper
• Oral terbinafine and erythema multiforme

  1995cited by this paper
• Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection

  1995cited by this paper
• Nail incorporation kinetics of terbinafine in onychomycosis patients

  1995cited by this paper
• Very short duration therapy with oral terbinafine for fingernail onychomycosis

  1995cited by this paper
• Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics

  1995cited by this paper
• Terbinafine in onychomycosis of the toenail: a novel treatment protocol.

  1995cited by this paper
• Overview of the use of terbinafine (Lamisil®) in children

  1995cited by this paper
• Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. LAGOS II Study Group.

  1995cited by this paper
• TERBINAFINE IN THE TREATMENT OF MAJOCCHI'S GRANULOMA

  1995cited by this paper
• Terbinafine and fixed drug eruption

  1995cited by this paper
• Treatment of Childhood Dermatophyte Infections with Oral Terbinafine

  1995cited by this paper
• Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group.

  1995cited by this paper
• Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis.

  1995cited by this paper
• Treatment of onychomycosis with terbinafine in patients with Down's syndrome

  1995cited by this paper
• Systemic treatment of skin candidosis: a randomized comparison of terbinafine and ketoconazole

  1994cited by this paper
• Neutropenia and pancytopenia associated with oral terbinafine.

  1994cited by this paper
• Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine.

  1994cited by this paper
• Two‐week oral treatment of tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double‐blind, multicentre study

  1994cited by this paper
• [Efficacy and tolerance of terbinafine (Lamisil) in a series of 50 cases of dermatophyte onychomycoses].

  1994cited by this paper
• Black piedra: the first case treated with terbinafine (Lamisil®)

  1994cited by this paper
• A double‐blind, randomized, stratified controlled study of the treatment of tinea imbricata with oral terbinafine or itraconazole

  1994cited by this paper
• Levels of terbinafine in plasma, stratum corneum, dermis–epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days

  1994cited by this paper
• [Drug-induced liver damage caused by antirheumatic drugs--antirheumatic therapy in pre-existing liver damage].

  1994cited by this paper
• One‐week therapy with oral terbinafine in cases of tinea cruris/corporis

  1994cited by this paper
• Human Trichophyton equinum infection treated with terbinafine

  1994cited by this paper
• A multinational pharmacoeconomic analysis of oral therapies for onychomycosis

  1994cited by this paper
• Terbinafine in onychomycosis with involvement by non‐dermatophytic fungi

  1994cited by this paper
• Terbinafine and erythema multiforme

  1994cited by this paper
• Stevens-Johnson syndrome after terbinafine therapy.

  1994cited by this paper
• Terbinafine-associated hepatic injury.

  1994cited by this paper
• Cost‐effectiveness analysis for onychomycosis therapy in Canada from a government perspective

  1994cited by this paper
• Elimination Kinetics of Terbinafine from Human Plasma and Tissues following Multiple-Dose Administration, and Comparison with 3 Main Metabolites

  1994cited by this paper
• Efficacité et tolérance de la terbinafine (Lamisil) dans une série de 50 onychomycoses à dermatophytes.

  1994cited by this paper
• Adverse Drug Reactions: A Practical Guide to Diagnosis and Management

  1994cited by this paper
• Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for four weeks.

  1993cited by this paper
• Effects of terbinafine exposure on the ultrastructure of Trichophyton interdigitale

  1993cited by this paper
• Hepatitis associated with terbinafine treatment.

  1993cited by this paper
• Terbinafine in chronic paronychia and candida onychomycosis

  1992cited by this paper
• Clinical singgnificance of interactions with antifungal agents

  1992cited by this paper
• An open clinical pilot study of the efficacy and safety of oral terbinafine in dry non‐inflammatory tinea capitis

  1992cited by this paper
• Short‐duration therapy with terbinafine for dermatophyteonychomycosis: A multicentre trial

  1992cited by this paper
• Dose‐proportional pharmacokinetics of terbinafine and its N‐demethylated metabolite in healthy volunteers

  1992cited by this paper
• Single dose treatment of fungal nail disease.

  1992cited by this paper
• Azoles, allylamines and drug metabolism.

  1992cited by this paper
• A randomized treatment duration‐finding study of terbinafine in onychomycosis

  1992cited by this paper
• Treatment of onychomycosis with terbinafine

  1992cited by this paper
• Azoles, a48 llylamines and drug metabolism

  1992cited by this paper
• Terbinafine Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Superficial Mycoses

  1992cited by this paper
• Treatment of cutaneous sporotrichosis with terbinafine

  1992cited by this paper
• Descriptive epidemiology of agranulocytosis.

  1992cited by this paper
• Terbinafine: Mode of action and properties of the squalene epoxidase inhibition

  1992cited by this paper
• Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat.

  1991cited by this paper
• Meta-analysis for combining Bayesian probabilities.

  1991cited by this paper
• Terbinafine and onychomycosis.

  1991cited by this paper
• A comparative study of terbinafine versus griseofulvin in 'dry-type' dermatophyte infections.

  1991cited by this paper
• Terbinafine and onychomycosis.

  1991cited by this paper
• Successful 2‐week treatment with terbinafine (Lamisil®) for moccasin tinea pedis and tinea manuum

  1991cited by this paper
• The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.

  1990cited by this paper
• [Drug-induced liver damage from the clinical viewpoint].

  1990cited by this paper
• A comparative double‐blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris

  1990cited by this paper
• Pharmacokinetics of Lamisil® in humans

  1990cited by this paper
• How orally administered terbinafine reaches the stratum corneum

  1990cited by this paper
• Terbinafine (Lamisil) versus griseofulvin in moccasin type tinea pedis

  1990cited by this paper

• Survey on the Prevalence of Terbinafine-Resistant Trichophyton spp. with Squalene Epoxidase Mutations.

  2025cites this paper
• Formulation and Evaluation of Terbinafine HCL loaded Nanoparticles for Transungual delivery of drug in Fungal infection

  2025cites this paper
• Relative impact of traditional vs. newer oral antifungals for dermatophyte toenail onychomycosis: a network meta-analysis study.

  2023cites this paper
• Solubility Determination and Thermodynamic Correlation for Terbinafine Hydrochloride in Several Mono-solvents from 283.15 to 323.15 K

  2023cites this paper
• Clinical Manifestations and Management of Terbinafine-Induced Acute Generalized Exanthematous Pustulosis

  2023cites this paper
• Dehydrative Cross-Coupling for C-N Bond Construction under Transition-Metal-Free Conditions.

  2022cites this paper
• Determination of terbinafine in healthy Chinese human plasma using a simple and fast LC-MS/MS method and its application to a bioequivalence study.

  2022cites this paper
• Multistep batch-flow hybrid synthesis of a terbinafine precursor

  2021cites this paper
• A multicentre, randomised, parallel‐group, double‐blind, vehicle‐controlled and open‐label, active‐controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis

  2021cites this paper
• A facile one-pot synthesis of 2-(prop-2-yn-1-ylidene)-2,3-dihydro-1,4-thiazepines

  2020cites this paper
• Onychomycosis: a review

  2020cites this paper
• Terbinafine-induced lichenoid drug eruption: case report and review of terbinafine-associated cutaneous adverse events.

  2020influential citation
• Computationally Assessing the Bioactivation of Drugs by N-Dealkylation.

  2018cites this paper
• Cross-coupling of 1,1-difluoro-1-en-3-yn-2-yl tosylates with arylboronic acids: A new approach to 2-aryl-1,1-difluoro-1,3-enynes

  2017cites this paper
• Solubility and thermodynamics of terbinafine hydrochloride in different neat and binary solvents: Measurement, correlation and molecular interactions

  2017cites this paper
• Novel investigational therapies for onychomycosis: an update

  2016cites this paper
• Terbinafine hydrochloride nanovesicular gel: In vitro characterization, ex vivo permeation and clinical investigation.

  2016cites this paper
• Terbinafine hydrochloride loaded liposome film formulation for treatment of onychomycosis: in vitro and in vivo evaluation

  2016cites this paper
• Past, Present, and Future of Antifungal Drug Development

  2016cites this paper
• Comparison of Oral Terbinafine with Itraconazole in the Treatment of Tinea Pedis Tinea Pedis Tedavisinde Oral Terbinafin ve İtrakonazolun Karşilaştirilmasi

  2015cites this paper
• Terbinafine susceptibility and genotypic heterogeneity in clinical isolates of Trichophyton mentagrophytes by random amplified polymorphic DNA (RAPD).

  2015cites this paper
• The relationship between the prenatal exposure to terbinafine and abnormal skin development in the newborn rats.

  2015influential citation
• Skin adverse effects with the administration of systemic terbinafine

  2015cites this paper
• Efectos adversos cutáneos con la administración de terbinafina sistémica

  2015cites this paper
• Stereoselective synthesis of allylamines by iron-catalyzed cross-coupling of 3-chloroprop-2-en-1-amines with grignard reagents. Synthesis of naftifine

  2014cites this paper
• Fe-catalyzed cross-coupling of 3-chloroprop-2-en-1-ylamines with sec-butylmagnesium bromide

  2014cites this paper
• Novel topical formulations of Terbinafine-HCl for treatment of onychomycosis.

  2013cites this paper
• Single crystal structure, solid state characterization and dissolution rate of terbinafine hydrochloride.

  2013cites this paper
• Stereoselective synthesis of conjugated fluoro enynes.

  2012cites this paper
• Terbinafine inhibits oral squamous cell carcinoma growth through anti‐cancer cell proliferation and anti‐angiogenesis

  2012cites this paper
• Comparison of once-daily versus twice-weekly terbinafine administration for the treatment of canine Malassezia dermatitis - a pilot study.

  2012cites this paper
• Transdermal iontophoretic delivery of terbinafine hydrochloride: quantitation of drug levels in stratum corneum and underlying skin.

  2010cites this paper
• Iontophoresis mediated in vivo intradermal delivery of terbinafine hydrochloride.

  2010cites this paper
• Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway.

  2010cites this paper
• Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

  2009cites this paper
• DETERMINATION OF THE PERMEABILITY OF BIOLOGICAL MEMBRANES TO VARIOUS CHEMICAL MARKERS, INCLUDING ANTI-HIV DRUGS

  2009cites this paper
• Transcriptional profiles of response to terbinafine in Trichophyton rubrum

  2009cites this paper
• Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development.

  2009cites this paper
• Insights into the structure, function, and regulation of human cytochrome P450 1A2.

  2009cites this paper
• Study on herb-drug interactions

  2009cites this paper
• Inhibition of the ERK phosphorylation plays a role in terbinafine-induced p21 up-regulation and DNA synthesis inhibition in human vascular endothelial cells.

  2008cites this paper
• SP1-regulated p27/Kip1 gene expression is involved in terbinafine-induced human A431 cancer cell differentiation: an in vitro and in vivo study.

  2008cites this paper
• Identificação e caracterização cromossomal de 9 loci de Leishmania (L.) major relacionados com resistência a inibidores da via de biossíntese do ergosterol

  2008cites this paper
• Modes of Action of the New Arylguanidine Abafungin beyond Interference with Ergosterol Biosynthesis and in vitro Activity against Medically Important Fungi

  2008cites this paper
• Updates in therapeutics for veterinary dermatology.

  2006cites this paper
• Catalytic four-component assembly based on allenylboronate platform: new access to privileged allylic amine structures.

  2006cites this paper
• Involvement of proapoptotic Bcl-2 family members in terbinafine-induced mitochondrial dysfunction and apoptosis in HL60 cells.

  2006cites this paper
• [Rhabdomyolisis and terbinafine].

  2006cites this paper
• Rabdomiólisis y terbinafina

  2006cites this paper
• Terbinafine-Induced Subacute Cutaneous Lupus Erythematosus

  2005cites this paper
• Current use of anti-infectives in dermatology

  2005cites this paper
• Inhibition of human vascular endothelial cells proliferation by terbinafine

  2004cites this paper
• Spontaneous Tolerance to Terbinafine-Induced Lichenoid Drug Eruption

  2004cites this paper
• Terbinafine Resistance Mediated by Salicylate 1-Monooxygenase in Aspergillus nidulans

  2004cites this paper
• Disseminated dermatophytosis caused by Microsporum gypseum in an AIDS patient: response to terbinafine and amorolfine

  2004cites this paper
• Oral Terbinafine-Induced Bullous Pemphigoid

  2003cites this paper
• Allgemeine Therapie von Haarkrankheiten

  2003cites this paper
• Update on antifungal therapy.

  2003cites this paper
• Avaliação de drogas antifúngicas no tratamento de camundongos BALB/c inoculados com o Lacazia loboi

  2003cites this paper
• In vitro and in vivo studies of the anticancer action of terbinafine in human cancer cell lines: G0/G1 p53‐associated cell cycle arrest

  2003cites this paper
• IN VITRO AND IN VIVO STUDIES OF THE ANTICANCER ACTION OF TERBINAFINE IN HUMAN CANCER CELL LINES : G 0 / G 1 P 53-ASSOCIATED CELL CYCLE ARREST

  2003cites this paper
• New agents for the treatment of systemic fungal infections – current status

  2002cites this paper
• Desipramine toxicity with terbinafine.

  2002cites this paper
• Identification of genes involved in terbinafine resistance in Aspergillus nidulans

  2002cites this paper
• Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans

  2002cites this paper
• Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil.

  2002cites this paper
• Drugs in pregnancy. Drugs to avoid.

  2001cites this paper
• Terbinafine-induced subacute cutaneous lupus erythematosus.

  2001cites this paper
• Association between terbinafine and arthralgia, fever and urticaria: symptoms or syndrome?

  2001cites this paper
• Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity.

  2001cites this paper
• Fixes Arzneimittelexanthem auf Terbinafin mit charakteristischem Verteilungsmuster eines Baboon-Syndroms

  2001cites this paper
• Reversible agranulocytosis associated with oral terbinafine in a pediatric patient.

  2001cites this paper
• Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis.

  2001cites this paper
• [Reproducible drug exanthema to terbinafine with characteristic distribution of baboon syndrome].

  2001cites this paper
• The use of the new oral antifungal agents, itraconazole, terbinafine, and fluconazole to treat onychomycosis and other dermatomycoses

  2001cites this paper
• Drugs to avoid

  2001cites this paper
• Granuloma tricofítico, comunicación de un caso

  2000cites this paper
• Oral antifungal agents used in dermatology

  2000cites this paper
• Drugs to avoid in pregnancy

  2000cites this paper
• An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents

  2000cites this paper
• Antifungal drug interactions

  2000cites this paper
• Current management of onychomycosis and dermatomycoses

  2000cites this paper
• Acute generalized exanthematous pustulosis associated with oral terbinafine

  2000cites this paper
• Current Management of Onychomycosis and Dermatomycoses.

  2000cites this paper
• A Risk-Benefit Assessment of the Newer Oral Antifungal Agents Used to Treat Onychomycosis

  2000cites this paper
• Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet.

  2000cites this paper
• Onychomycosis. Treatment, quality of life, and economic issues.

  2000cites this paper
• Dermatophyte infections in human immune deficiency virus (HIV) disease.

  2000cites this paper
• The use of systemic antimycotics in dermatotherapy.

  2000cites this paper
• HIV disease: mucocutaneous fungal infections in HIV disease.

  2000cites this paper
• Tinea capitis.

  2000cites this paper
• Onychomycosis in the Elderly

  2000cites this paper
• Comparative study between terbinafine 1% emulsion-gel versus ketoconazole 2% cream in tinea cruris and tinea corporis.

  2000cites this paper
• Tinea manus treated with 1‐week itraconazole vs. terbinafine

  2000cites this paper
• Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA

  1999cites this paper
• Correspondence

  1999cites this paper
• [Terbinafine].

  1999cites this paper
• Pharmacotherapy of Tinea Capitis

  1999cites this paper
• Management of Onychomycoses

  1999cites this paper
• Safety review of the oral antifungal agents used to treat superficial mycoses.

  1999cites this paper